AI empowers the implementation of new drug regulatory policies, highlighting the value of ChinaAMC SSE STAR Medicine ETF
I'm LongbridgeAI, I can summarize articles.
As of April 3, 2026, the SSE STAR Biology and Medicine Index fell by 2.03%. The performance of constituent stocks varied, with HUIYU PHARMACEUTICAL rising by 4.77%, while HitGen dropped by 5.97%. The ChinaAMC SSE STAR Biology and Medicine ETF fell by 2.26%, with the latest quote at 1.08 yuan. The National Medical Products Administration released a new policy to promote the integration of artificial intelligence and drug regulation. Huaxin Securities pointed out that the pharmaceutical and biotechnology sector will become an emerging pillar industry, with the development model of innovative drugs shifting to a comprehensive drive. The market is focused on the quality of clinical data and long-term value
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments